Webinar Archive

This webinar, led by the task force co-chairs, will focus on why a joint HTAi-ISPOR Task Force was formed to develop guidance, they will present the minimum set of considerations on the use of deliberative processes in HTA (checklist), and the approach used. During the webinar, participants will have the opportunity to discuss what efforts could be made to ensure the appropriate use and uptake of the guidance, potential gaps and what more might be needed.

Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.

Join us for the Signal event on September 27, 2022 to learn about the Danish experience with ATMP valuation approach and development of an innovative outcomes-based pricing agreement between pharma and payers. You will gain insight into the practicalities of stakeholder involvement and data requirements, and overall learnings from the outcomes-based pricing agreement experience from a multistakeholder perspective.

Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.

The attrition rate of drug programs in early-stage development is high, with two-thirds of preclinical programs failing to move successfully to Phase 1. How do we better inform translational R&D decisions to de-risk investments and help increase probability of success?

Join this panel discussion to hear experts from patient advocacy, health literacy, and Health Economics and Outcomes Research (HEOR).

On Aug 7th, 2022, the US House of representatives passed a bill on budget reconciliation which included a section on US Drug pricing reform (Part B). The reform requires federal government to negotiate drug prices under Medicare to ensure significant discounts on branded therapies and eliminate annual price increases. The bill further requires pharmaceutical companies to pay rebates if drug prices rise faster than inflation for Medicare and private insurances. Join experts Anna Forsythe, Vice President Value & Access at Cytel, and Dr. Edmund Pezalla, Founder & CEO of Enlightenment Bioconsult, as they discuss the impact of this reform on pricing of new and established therapies and the potential role of health economic evidence to justify product value in future negotiations with CMS.

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments. We know patient recruitment can be challenging even for non-complex trials, but this issue is exacerbated for rare disease studies due to the much smaller patient populations involved. This can lead to lengthy delays in bringing what can be cutting-edge and potentially life-changing therapies to market.

Despite all of their promise, newer medicines, especially those based on advanced technologies, have been met with unprecedented challenges in scaling up manufacturing, quality control and commercial launch. Hear how developers have approached different aspects of the manufacturing process to bring new and innovative treatments to patients.

On Aug 7th, 2022, the US House of representatives passed a bill on budget reconciliation which included a section on US Drug pricing reform (Part B). The reform requires federal government to negotiate drug prices under Medicare to ensure significant discounts on branded therapies and eliminate annual price increases. The bill further requires pharmaceutical companies to pay rebates if drug prices rise faster than inflation for Medicare and private insurances.

Join Precision ADVANCE and Endpoints News as we kick off Cell & Gene Day, where we'll convene three expert panels to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization.

Lab of the future requires a modern, connected, adaptable solution that manages work traditionally done in siloed – and now outdated – ELN and LIMS solutions. With a shared solution connecting R&D data, teams can manage samples and processes with seamless handoffs and complete traceability. Join us for an engaging discussion with Dan Chapman, Director of the Experiment Design and Execution Platform Product at Merck, and experts from Zifo and Benchling.

Join Dr. Greg Johnson, CEO of Hospital Medicine and Chief Diversity Officer at Sound Physicians, for an engaging discussion where he will share how to confront these care gaps and advance health equity in hospital medicine.

This solution-focused, truth-packed session is a great fit for market access marketers, brand marketers and sales leaders who are interested in making their brands’ market access a top advantage over the competition.

Join your peers to learn how pharmaceutical and life sciences organizations use conversational AI to automate workflows and communication to increase efficiency and reduce costs. Panelists from Pfizer and other leaders in the industry will discuss how artificial intelligence impacts and improves pharma's relationships with physicians, consumers, insurers, and regulators. You will gain insights into how mobile apps can streamline the treatment journey and the power of automated communication to improve awareness, access, and adherence. Finally, you'll also walk away with real-life examples of how physicians harness innovation and digital tactics for new patient acquisition and patient support. Come prepared with questions so you can drive superior results for your organization.

Data standardization is across medical device types and manufactures is exceedingly uncommon and acts as a barrier to capturing and integrating data to improve quality of care. Baylor, Scott, and White Health tackled this problem by bringing together an interdisciplinary group of staff and implementing a scalable system enterprise-wide. Join Lisa Kilgore and Nathan Winn from Baylor and Scott in a webinar this Monday, July 25th, to learn more.

Once again Congress is barreling towards drug pricing reform. STAT will sit down with key decision makers to talk about the latest developments from Capitol Hill and the White House.

Artificial intelligence could play a role in the future of patient care — managing everything from office visits to surgery and radiology. A look at how researchers aim to create a "data economy" to ensure that these new technologies live up to their potential.

Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what’s at stake and what steps can be taken to prevent a devastating attack? And what are the best strategies for both big and small organizations?

In this webinar, experts will share insights into intranasal vaccine formulation development and discuss the current state of the art in intranasal vaccine production from development to commercial scale. In addition, a detailed discussion on the challenges and opportunities of intranasal approaches will be presented including the importance of device selection in determining product performance.

Join Dr. Jessica Paulus as she explores opportunities and challenges with using RWD in conducting CER.